Cover Image
市場調查報告書

Spherix Incorporated的產品平台分析

Spherix Incorporated - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 224729
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
Spherix Incorporated的產品平台分析 Spherix Incorporated - Product Pipeline Review - 2014
出版日期: 2014年06月15日 內容資訊: 英文 32 Pages
簡介

本報告提供Spherix Incorporated的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Spherix Incorporated的基本資料

Spherix Incorporated概要

  • 主要資訊
  • 企業資料

Spherix Incorporated:R&D概要

  • 主要的治療範圍

Spherix Incorporated:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Spherix Incorporated:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Spherix Incorporated:藥物簡介

  • SPX-10624258
  • (SPX-106 + D-tagatose)
  • SPX-100
  • SPX-7233801
  • SPX-8522876
  • SPX-8818309
  • SPX-8818440

Spherix Incorporated:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Spherix Incorporated:最近的開發平台趨勢

Spherix Incorporated:企業發表

Spherix Incorporated:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04999CDB

Global Markets Direct's, 'Spherix Incorporated - Product Pipeline Review - 2014', provides an overview of the Spherix Incorporated's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Spherix Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Spherix Incorporated including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Spherix Incorporated's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Spherix Incorporated's pipeline products

Reasons to buy

  • Evaluate Spherix Incorporated's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Spherix Incorporated in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Spherix Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Spherix Incorporated and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Spherix Incorporated
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Spherix Incorporated and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Spherix Incorporated Snapshot
    • Spherix Incorporated Overview
    • Key Information
    • Key Facts
  • Spherix Incorporated - Research and Development Overview
    • Key Therapeutic Areas
  • Spherix Incorporated - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Spherix Incorporated - Pipeline Products Glance
    • Spherix Incorporated - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Spherix Incorporated - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Spherix Incorporated - Drug Profiles
    • SPX-10624258
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (SPX-106 + D-tagatose)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPX-100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPX-7233801
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPX-8522876
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPX-8818309
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPX-8818440
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Spherix Incorporated - Pipeline Analysis
    • Spherix Incorporated - Pipeline Products by Target
    • Spherix Incorporated - Pipeline Products by Molecule Type
    • Spherix Incorporated - Pipeline Products by Mechanism of Action
  • Spherix Incorporated - Recent Pipeline Updates
  • Spherix Incorporated - Company Statement
  • Spherix Incorporated - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Spherix Incorporated, Key Information
  • Spherix Incorporated, Key Facts
  • Spherix Incorporated - Pipeline by Indication, 2014
  • Spherix Incorporated - Pipeline by Stage of Development, 2014
  • Spherix Incorporated - Monotherapy Products in Pipeline, 2014
  • Spherix Incorporated - Combination Treatment Modalities in Pipeline, 2014
  • Spherix Incorporated - Phase I, 2014
  • Spherix Incorporated - Preclinical, 2014
  • Spherix Incorporated - Pipeline by Target, 2014
  • Spherix Incorporated - Pipeline by Molecule Type, 2014
  • Spherix Incorporated - Pipeline Products by Mechanism of Action, 2014
  • Spherix Incorporated - Recent Pipeline Updates, 2014
  • Spherix Incorporated, Subsidiaries

List of Figures

  • Spherix Incorporated - Pipeline by Top 10 Indication, 2014
  • Spherix Incorporated - Pipeline by Stage of Development, 2014
  • Spherix Incorporated - Monotherapy Products in Pipeline, 2014
  • Spherix Incorporated - Pipeline by Top 10 Target, 2014
  • Spherix Incorporated - Pipeline by Top 10 Molecule Type, 2014
  • Spherix Incorporated - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top